Results 61 to 70 of about 4,705,551 (307)
Mechanism of Action and Target Identification: A Matter of Timing in Drug Discovery
iScience, 2020 Summary: Two opposing viewpoints are held regarding the need for understanding a drug's molecular target and mechanism of action. One extreme viewpoint is that it is unnecessary, because, after all, there are many beneficial drugs in use for which the ...
Ronald L. Davis
doaj
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source
INNOVATIONS in Pharmacy, 2017 As a unique and versatile undergraduate degree program, a Bachelor of Science in Pharmaceutical Sciences (BSPS) is offered by a number of colleges/schools of pharmacy.
Gabriella Baki +2 more
doaj +1 more source
Molecular Oncology, EarlyView.Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed +8 more
wiley +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source
The Science of Differentiated Medicines: The 9th APS PharmSci Conference @FIP 2018
British Journal of Pharmacy, 2019 The Academy of Pharmaceutical Sciences (APSGB) hosts the annual Pharm Sci Conference, the UK’s premier pharmaceutical sciences event championing ‘The Science of Medicines’.
John Wahlich
doaj +1 more source
Molecular Oncology, EarlyView.Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon +13 more
wiley +1 more source
iScience, 2023 Summary: Encapsulated cell therapy holds a great potential to deliver sustained levels of highly potent therapeutic proteins to patients and improve chronic disease management. A versatile encapsulation device that is biocompatible, scalable, and easy to
Julien Grogg +10 more
doaj
Crystallization for Pharmaceutical and Food Science
Current Pharmaceutical Design, 2018 Xichang Wang +3 more
openaire +3 more sources
Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management
Molecular Oncology, EarlyView.DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez +5 more
wiley +1 more source